Experimental results demonstrated that under the help of FUS, MB-shBirc5-lipo-NGR effectively breached the BBB, specifically targeted C6 glioma cells through NGR/CD13 interaction, and ultimately inhibited glioma growth in an orthotopic glioma rat model. This evidence concerns the gene RTN4R and central nervous system cancer.